SHLP2: A Literature Course on What the Studies Report

SHLP2 — short for small humanin-like peptide 2 — appears in the published literature as a mitochondria-derived peptide studied in cell cultures, rodent models and human observational cohorts. This page organises that literature into six modules. It does not describe protocols, and it does not tell anyone what to do with any compound. This page is for educational purposes only and is not medical advice; consult a licensed physician for any health question.

Each module below ends with an explicit statement of what the evidence cannot support, because with SHLP2 the gaps are as informative as the findings.

Module 1: What SHLP2 Is and How It Has Been Studied

Definition and class

SHLP2 belongs to a family of small peptides (commonly numbered SHLP1 through SHLP6) that are encoded by short open reading frames inside the mitochondrial genome, in the same 16S ribosomal RNA region that encodes humanin. Peptides from this genomic neighbourhood are grouped together as mitochondria-derived peptides (MDPs), a class that also includes humanin and MOTS-c. SHLP2 is therefore not a synthetic drug scaffold invented in a laboratory; it is described as an endogenous peptide that can also be synthesised for experimental use.

Origin and forms encountered in the literature

• Endogenous circulating peptide. Human studies have measured SHLP2 in plasma using immunoassays, treating it as a biomarker rather than an intervention.
• Synthetic peptide used in experiments. Cell and animal papers applied synthesised SHLP2 to cultures or administered it to rodents.
• Naturally occurring sequence variant. Researchers described a naturally occurring mitochondrial DNA variant that alters the SHLP2 sequence and reported that it behaved as a protective factor in Parkinson's disease analyses in a 2024 Molecular Psychiatry study.

How it has been studied

The human work is observational. One case-control analysis reported that lower circulating levels of SHLP2 were associated with prostate cancer risk in a 2017 Oncotarget study. A separate metabolic cohort analysis reported that plasma SHLP2 associated positively with android fat and liver fat in people without diabetes in a 2021 BBA General Subjects study. Neither of those human papers gave SHLP2 to anyone; both measured what was already circulating.

The interventional work sits in cells and rodents: retinal pigment epithelial models, pre-osteoblast cultures, an allergic asthma mouse model, and hypothalamic energy-balance experiments in mice.

Limits of the evidence in this module

There is no published clinical trial of administered SHLP2 in the verified literature reviewed here. The class label "mitochondria-derived peptide" describes where a sequence comes from, not a shared safety profile or a shared clinical role. Associations measured in plasma cannot establish that raising or lowering SHLP2 changes any outcome.

Module 2: Mechanism as Described in the Literature

A receptor and a central nervous system pathway

The most mechanistically detailed report is a 2023 Nature Communications study, in which researchers reported that SHLP2 acted through the muscarinic acetylcholine receptor CHRM3 and that SHLP2 activated hypothalamic neurons involved in energy homeostasis in mice. That framing matters: it positions SHLP2 as a signalling peptide with an identified surface receptor, rather than purely as an intracellular mitochondrial factor.

Cell-stress and mitochondrial pathways

Several papers describe SHLP2 in the context of oxidative stress. In retinal models relevant to macular degeneration, the study reported protective effects of SHLP2 on cells under stress and on mitochondrial function in a 2018 Scientific Reports paper. In bone-lineage cells, researchers reported that SHLP2 acted on oxidative stress-induced inflammaging endpoints in pre-osteoblastic cultures in a 2025 Scientific Reports paper.

Inflammatory cell death

An airway study framed SHLP2 in terms of pyroptosis, reporting that SHLP2 alleviated allergic asthma features by inhibiting ETV5/GSDMD signalling in a 2025 Cellular Signalling paper. Gasdermin D (GSDMD) is the pore-forming executor of pyroptosis, so the proposed mechanism is suppression of an inflammatory form of cell death rather than generic anti-inflammatory activity.

Genetic variation as indirect mechanistic evidence

The Parkinson's disease work approached mechanism from the genetics side, reporting that a naturally occurring SHLP2 variant functioned as a protective factor in the 2024 Molecular Psychiatry study. Variant-based evidence links sequence to outcome without requiring that anyone be dosed.

Limits of the evidence in this module

These mechanisms were described in different tissues, species and disease models, and no paper in this set demonstrated that one mechanism explains the others. A receptor identified in hypothalamic neurons does not automatically explain retinal, osteoblastic or airway findings. Mechanistic plausibility is not efficacy, and none of these pathways has been confirmed in humans given SHLP2.

Module 3: Reported Outcomes by Study

The table summarises the models, endpoints and reported directions of effect. Nothing here should be read as a promise of benefit; each row is a description of what one paper reported in one model.

Reading the two human papers together

The directions are not obviously consistent with a single "more is better" story. Lower circulating SHLP2 was reported alongside higher prostate cancer risk in the 2017 Oncotarget analysis, while higher plasma SHLP2 was reported alongside greater android and liver fat in the 2021 cohort analysis. Both are cross-sectional associations in different populations with different endpoints, and neither established causal direction.

Limits of the evidence in this module

Every interventional result above came from cells or rodents. Sample sizes, assay methods and populations differ across the human studies. No paper in this set reported patient-relevant clinical outcomes after SHLP2 administration, and no independent replication of any single interventional finding is represented here.

Module 4: Shlp2 Side Effects: What Studies Report

The honest summary is that the verified literature contains no adverse-event dataset for SHLP2. The studies were designed to test mechanisms and disease-model endpoints, not tolerability.

• The energy-homeostasis work was conducted in mice and reported neuronal and metabolic endpoints rather than a safety or toxicology assessment in the 2023 Nature Communications study.
• The macular degeneration work was carried out in laboratory models of retinal disease and reported protective cellular endpoints, without human adverse-event reporting, in the 2018 Scientific Reports paper.
• The asthma paper reported inflammatory and pyroptosis endpoints in a disease model rather than treatment-emergent adverse events in the 2025 Cellular Signalling study.
• The bone-cell paper reported changes in oxidative stress and inflammaging markers in culture, a setting in which clinical adverse events cannot be observed at all, in the 2025 Scientific Reports paper.

The two human papers measured endogenous SHLP2 concentrations rather than administering the peptide, so they generate no tolerability information either, as reported in the 2017 Oncotarget study and the 2021 BBA General Subjects study.

Limits of the evidence in this module

Absence of reported adverse events in preclinical mechanistic papers is not evidence of safety. There is no published dose-ranging toxicology, no immunogenicity assessment, no long-term exposure data and no human tolerability record in this literature set. Any statement that SHLP2 is "well tolerated" would not be supported by these papers.

Module 5: Pharmacokinetics Where Data Exist

Pharmacokinetics is the weakest area of the SHLP2 record. What exists is closer to endogenous concentration measurement than to classical PK.

Measurement of circulating peptide

Human plasma SHLP2 has been quantified as an analyte in observational research: circulating levels were compared between groups and reported as a candidate biomarker in the 2017 Oncotarget study, and plasma concentrations were correlated with body-composition measures in the 2021 BBA General Subjects study. Those papers establish that the peptide is detectable in blood and that concentrations vary between individuals.

Exposure in animal work

Rodent experiments involved administration of SHLP2 and reported downstream neuronal and metabolic effects in the 2023 Nature Communications study, but the abstract-level record for this course does not provide human absorption, distribution, metabolism or elimination parameters.

What is not established

• No published human half-life, clearance or volume of distribution.
• No comparative bioavailability data across routes of administration in humans.
• No established therapeutic concentration range, because no therapeutic use has been established.
• No standardised reference interval for plasma SHLP2 across laboratories and assay platforms.

Limits of the evidence in this module

Assay-based plasma levels depend on the antibody and platform used, so values are not automatically comparable between studies. Rodent exposure does not translate directly to humans for small peptides, which are typically subject to rapid proteolysis. Without human PK, no statement about frequency, route or exposure duration can be grounded in this literature.

Module 6: Regulatory Status, Stated Factually

Approved products

There is no SHLP2 product approved by the U.S. Food and Drug Administration, and the peptide does not appear in the verified literature as an approved medicine in any jurisdiction. The publications summarised here are laboratory, animal and observational research reports, not regulatory submissions.

Research-use-only material

Peptides that exist only in the research literature are typically supplied as research-use-only (RUO) chemicals. RUO labelling is a regulatory statement that the material has not been evaluated for human use and is intended for laboratory investigation. RUO status is not an abbreviated approval pathway, and it carries no assurance of identity, purity or sterility comparable to a drug product manufactured under current good manufacturing practice.

Compounding

In the United States, a substance used by a 503A compounding pharmacy or a 503B outsourcing facility must generally meet statutory criteria under the Federal Food, Drug, and Cosmetic Act — for example, being a component of an FDA-approved drug, having an applicable USP or NF monograph, or appearing on the relevant FDA bulk drug substances list. A peptide with no approved product, no monograph and no bulks listing does not satisfy those conditions. Nothing in the verified literature indicates that SHLP2 has been evaluated within those compounding frameworks.

Limits of the evidence in this module

Regulatory status changes over time and differs by country; the descriptions above are general and factual rather than jurisdiction-specific. This section is informational only and is not legal advice.

What the Studies Did Not Test

Reading the seven papers together, the untested territory is large:

1. Clinical efficacy. No randomised controlled trial of SHLP2 administration appears in this literature; the disease-model findings in the 2018 retinal paper and the 2025 asthma paper were reported in laboratory models only.
2. Human safety. No tolerability, immunogenicity or long-term exposure data were reported in the mouse work described in the 2023 Nature Communications study.
3. Causality behind biomarker associations. Whether altered SHLP2 concentrations cause, follow or merely accompany the outcomes reported in the 2017 prostate cancer analysis and the 2021 fat-distribution analysis was not resolved.
4. Whether variant genetics translates to peptide administration. A protective variant reported in the 2024 Parkinson's disease study describes lifelong genetic exposure, not the effect of giving a peptide to an adult.
5. Ageing and bone outcomes in living organisms. The inflammaging endpoints reported in the 2025 pre-osteoblast study were cellular markers, not fracture, density or functional outcomes.

SHLP2 is best understood, on the current record, as an actively investigated endogenous signalling peptide with an identified receptor pathway and several promising-looking preclinical model results — and with essentially no human interventional evidence. This page is for educational purposes only and is not medical advice; consult a licensed physician before making any health decision.

References

• Mitochondria-derived peptide SHLP2 regulates energy homeostasis through the activation of hypothalamic neurons (Nature Communications, 2023)
• Characterizing the protective effects of SHLP2, a mitochondrial-derived peptide, in macular degeneration (Scientific Reports, 2018)
• SHLP2 alleviates allergic asthma by inhibiting ETV5/GSDMD signaling pathway-mediated pyroptosis (Cellular Signalling, 2025)
• A naturally occurring variant of SHLP2 is a protective factor in Parkinson's disease (Molecular Psychiatry, 2024)
• SHLP2 restores pre-osteoblastic cells against oxidative stress-induced inflammaging (Scientific Reports, 2025)
• Low circulating levels of the mitochondrial-peptide hormone SHLP2: novel biomarker for prostate cancer risk (Oncotarget, 2017)
• Plasma mitochondrial derived peptides MOTS-c and SHLP2 positively associate with android and liver fat in people without diabetes (Biochimica et Biophysica Acta General Subjects, 2021)